Objective: In the treatment of immune thrombocytopenia dexamethasone, rituximab, and cyclosporine combination therapies provided promising results in recent years. This study aimed to investigate the responses of patients with quadruple therapy which created by combining combinational therapies given in immune thrombocytopenia with eltrombopag.Methods: Four patients diagnosed with immune thrombocytopenia who received steroid in the first -line treatment and eltrombopag in the second-line treatment without achieving complete remission/partial remission were retrospectively evaluated in terms of the treatment they received and response rates. Results: received and response rates.Results:Patients with relapsed/refractory immune thrombocytopenia were treated by oral dexamethasone, oral cyclosporine and intravenous low-dose rituximab in addition to eltrombopag therapy. Eltrombopag treatment was continued at a dose of 50mg/day. No loading dose was given for cyclosporine, weekly blood cyclosporine level was monitored for toxicity and the treatment was titrated to a target dose of 200 to 400 mu g/L. No toxicity-induced death, serious treatment-related adverse events, or non-adherence to treatment were observed. The 6-month response rate was 75% and the treatment was well tolerated. Two patients were still followed up by us with a complete response, while one our patient underwent splenectomy because of relapse after 6 months and is still being followed up with eltrombopag therapy. In one our patient, which was unresponsive, romiplastim treatment was applied but there was no response to this treatment either. The patient was referred to a clinical study.Conclusions: Our study showing that a combination of quadruple therapy can be a treatment option in patients with treatment-resistant immune thrombocytopenia is promising.